INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide and accounts for 3.3% of all cancer diagnoses in the United States. 1 Most patients with early stage HNSCC can be effectively treated with single-modality treatment using local radiation or surgical intervention. However, more than half of the estimated 36,000 Americans developing HNSCC in 2010 will present with locoregionally advanced stage disease and have a 5-year survival of less than 50%. 2 The use of platinum-based chemotherapy as a radiosensitizing agent has been shown to improve treatment outcomes but results in significant morbidity and mortality. As a result, exploring new treatments that target specific head and neck cancer cell pathways is of critical importance.
The discovery that epithelial tumors overexpress the epidermal growth factor receptor (EGFR) led to the development of targeted therapies in HNSCC. EGFR stimulation results in cell proliferation, circumvention of apoptosis, and increased tumor cell metastasis. In HNSCC, these events have been shown to be mediated downstream by the protein kinase B (AKT) signaling pathway. In addition, increasing levels of AKT activation correlates with an increase in the malignant potential of HNSCC. 3 AKT activation occurs by phosphorylation at the T308 and S473 residues and has been validated as a critical step in the initiation and maintenance of metastatic tumors. 4 However, it is unclear if there is a therapeutic benefit of AKT inhibition in head and neck cancer. To this end, we evaluate a novel AKT inhibitor currently in clinical trials to determine its potential in the treatment of head and neck cancers.
MK-2206 (Merck Research Laboratories, Rahway, NJ) has been shown to be an orally active, allosteric inhibitor of AKT that does not bind to the active site of AKT phosphorylation directly but instead alters the shape of AKT so that adenosine triphosphate (ATP) binding at the T308 and S473 residues is prevented. MK-2206 has been assessed for treatment of breast and colon cancer, but its role in head and neck cancer has not been established. When AKT is activated, the result is an increase in downstream signal transduction pathways involved in cell migration, proliferation, and metastasis. 5 Although AKT is known to be constitutively activated in a large percentage of HNSCC, inhibition of AKT to prevent metastatic spread has not been studied in this patient population.
Targeted therapy in the form of monoclonal antibody to EGFR is becoming increasingly important in treating HNSCC. EGFR is activated by ligand binding followed by homo-or heterodimerization with another member of the EGFR superfamily leading to increased recruitment of phosphoinositol-3-kinase (PI3K) and persistently high levels of AKT in the plasma membrane. The most commonly used targeted agent, cetuximab, has been shown to demonstrate a survival advantage compared with radiation alone in the treatment of patients with locoregionally advanced HNSCC. 6 In patients with recurrent/metastatic disease, however, overall survival was found to be improved by only 1 to 2 months. 7 The modest success of cetuximab highlights the need for new compounds that more effectively target the EGFR signaling pathway in HNSCC. In the present study, we investigate inhibition of the AKT pathway using MK-2206 as a viable strategy for preventing growth and metastasis of HNSCC in vitro and in vivo models. 
MATERIALS AND METHODS

Drugs and Chemicals
Cell Culture
The head and neck cancer cell lines SCC-1, SCC-5, FaDu, and Cal27 (ATCC, Manassas, VA) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) and supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin solution. All cells were cultured to 70% to 90% confluence before passage. Cells were incubated at 37 C in a humidified atmosphere containing 5% CO 2 . Normal dermal fibroblast isolation from primary culture has been described previously.
Cell Transformation
SCC-1 cells were plated at a density of 0.5 Â 10 5 in a 24-well plate, 24 hours before viral infection. Cells were cultured in 0.5 mL of complete optimal medium (with serum and antibiotics) and incubated at 37 C with 5% CO 2 overnight. Lentivirus was thawed in a 37 C water bath and prepared in a mixture of complete medium with Polybrene (Sigma, St. Louis, MO). Media was aspirated from plate wells and replaced with 0.5 mL of this prewarmed Polybrene/media mixture per well (for 24-well plate). Cells were infected by adding 10 lL of viral stock. The infected target cells were analyzed for transient expression or selected for stable expression using puromycin. Luciferase; Luc2 expression was screened for by imaging cells in 24-well plates with 150 lg/mL D-luciferin in the culture medium. Puromycin selection pressure was used to generate stable SCC-1 cell lines.
Flow Cytometry
Human cancer cell lines SCC-1, SCC-5, FaDu, and Cal27 were aliquoted (1 Â 10 5 cells/tube) and stained with calcein AM for cell viability assays (BD Pharmingen, San Diego, CA). Calcein was utilized as an early marker of apoptosis. Following appropriate washes, cells were analyzed for fluorescent counts using an Accuri C6 flow cytometer (Accuri Cytometers Inc., Ann Arbor, MI). All experimental groups were analyzed in triplicate.
Immunohistochemistry
Serial sections of 5-lm thickness were cut from the formalin-fixed, paraffin-embedded tissue blocks and floated onto charged glass slides (Super-Frost Plus; Fisher Scientific, Pittsburgh, PA) and dried overnight in a 60 C oven. A minimum of 10 serial hematoxylin and eosin (H&E)-stained sections were obtained from each tissue block and assessed for presence of tumor pathology. All sections subject to immunohistochemistry were deparaffinized and rehydrated before antigen retrieval. The tissue sections were heat treated with 0.01M Tris-1mM EDTA buffer (pH 9) using a pressure cooker (CEPC 800; Cook's Essentials, China) for 5 minutes at maximum pressure (15 lb/ in 2 ). Following antigen retrieval, all sections were gently washed in deionized water and then transferred to TBST (0.05M Tris-based solution in 0.15M NaCl with 0.1% vol/vol Triton-X-100, pH 7.6). Endogenous peroxidase was blocked with 3% hydrogen peroxide for 10 minutes. To further reduce nonspecific background staining, slides were incubated with 3% normal goat or horse serum for 20 minutes (Sigma, St. Louis, MO) according to the host where primary antibodies were produced. All slides were then incubated at 4 C overnight; rabbit anti-TUNEL (1:1,000, AbCam, Cambridge, MA) or rabbit antiKi67 (1:100, Santa Cruz Biotechnology, Santa Cruz, CA). Negative controls were achieved by eliminating the primary antibodies from the diluents. Following washing with TBST, peroxidase-conjugated goat anti-rabbit IgG (1:5,000, Jackson ImmunoResearch, West Grove, PA) were applied to the sections for 30 minutes at room temperature. Diaminobenzidine (DAB; ScyTek Laboratories, Logan, UT) was utilized as the chromogen, and hematoxylin (7211; Richard-Allen Scientific, Kalamazoo, MI) was used as the counterstain.
Cell Migration Assays
In vitro scratch assay was performed according to previously described methods. 8 Briefly, FaDu and SCC-1 cells were incubated for 12 hours in six-well culture plates containing DMEM and supplemented with 10% FBS and 1% penicillinstreptomycin solution. Once 100% confluence was observed, a 1-mm linear ''scratch'' was made in the adherent cell monolayer with a 200-lL pipette tip. The scratch area to be used for assay was marked with a permanent marker on the underside of the six-well plate. Debris was removed from wells by washing the cells once with 1 mL of the growth medium, which was then replaced with 3 mL of medium specific for the in vitro scratch assay. Assay medium containing 1% FBS with 100 nM MK-2206 was added to three wells in the treatment group and 1% DMSO vehicle to three wells in control group. Linear distance between cells on either side of the scratch was measured in 10 locations for each well at 0, 8, 16, and 24 hours.
FaDu and SCC-1 chemotaxis was assessed using a QCM cell migration assay (Millipore, Billerica, MA). Cells were incubated in a 96-well plate containing serum-free media. Each well contains a microporous polycarbonate membrane with 8 lM pore size. Cells of interest are pipetted onto the top of the insert and incubated with 1% FBS. Migratory cells move through the pores of the membrane and cling to the bottom of the polycarbonate membrane in response to a DMEM media with 10% FBS loaded into the bottom feeder tray. Cells that migrate through the membrane are then lysed and total protein is quantified using an enzyme-linked immunosorbent assay (ELISA) plate reader. The IC 50 of MK-2206 was found to be 1 lM, and we treated cells in both the scratch assay and the invasion assay with 100 nM to mitigate the antiproliferation effect of MK-2206 on migration assays.
Orothotopic Tongue Tumor Model
Athymic nude female mice aged 4 to 6 weeks were injected with luciferase expressing SCC-1 cells (2.5 Â 10 5 ) in the anterior portion of their tongues. Seven days after tumors were implanted, mice began treatment with 120 mg/kg MK-2206 (n ¼ 10 in each treatment group) or vehicle alone. Tongue tumors were measured before treatments every other day. Luciferase expression of SCC-1/Luc cells was assessed using a GE explore optics IVIS photon counter (Advanced Research Technologies-GE Healthcare, San Diego, CA) with a saturating dose of luciferin given 10 minutes before imaging by intraperitoneal injection once each week. At the end of treatment, mice were injected with cetuximab conjugated to Cy5.5 near infrared dye. After 48 hours, neck dissections were performed and cervical metastasis was assessed using the Pearl Impulse (LiCor, Lincoln, NE). Pathology samples were taken from positive and negative lymph nodes, and histologic analysis was performed to confirm optical imaging response (data not shown).
In Vivo Dosing With MK-2206
Treatment with MK-2206 was performed by oral gavage. MK-2206 was provided by Merck in powder form, and the agent was dissolved in DMSO and then diluted to 120 mg/kg with sterile water. A neonatal feeding tube was inserted into the stomach of anesthetized mice and dosed three times a week. The 120 mg/kg dose of MK-2206 has been previously established by others to be effective in vivo. In a western blot analysis of HNSCC tumors posttreatment, we found that a 120 mg/kg dose of MK-2206 was able to inhibit AKT kinase phosphorylation for 24 hours, without resulting weight loss observed at higher concentrations (data not shown).
MK-2206 Causes Apoptosis of SCC-1, SCC-5, FaDu, and Cal27 Cells In Vitro
The in vitro effect of logarithmic dose of MK-2206 on SCC-1, SCC-5, FaDu, OSC-19, and Cal27 cells was assessed using flow cytometry with calcein AM as a marker of cell viability. Of the cancer cell lines, SCC-1 was the most sensitive, with IC50 ¼ 1.02 6 0.42 lM (Fig. 1) . SCC-1 and FaDu cells were found to provide the greatest therapeutic index and were selected for use in our animal experiments. The effect of MK-2206 on phosphorylation of AKT, and phosphorylation of three direct substrates of AKT (GSK3b, BAD, and PRAS40), was assessed by Western blotting (Fig. 1C) . We found that monotherapy with 1, 10, or 100 lM MK-2206 was sufficient to reduce expression of p-GSK3b, p-BAD, or p-PRAS40 in vitro. Reducing AKT phosphorylation corresponded with a decrease in cellular metabolism as measured by an ATP ELISA assay (Fig. 1D) . Total AKT cellular protein remained consistent with micromolar MK-2206 treatment, but expression of p-AKT was inhibited with MK-2206 at concentrations greater than 1 lM.
Inhibition of AKT Prevents Cell Migration and Chemotaxis In Vitro
The effect of MK-2206 on cell migration was assessed in vitro with a wound assay and analysis of cell invasion (Fig. 2) . SCC-1 and FaDu cells were grown to confluence, and a wound assay was performed in the presence or absence of 0.1 lM MK-2206. Images of cell migration for MK-2206-treated culture plates ( Fig. 2A) show delayed migration of SCC-1 cells at 8 (P ¼ .04), 16 (P < .001), and 24 hours (P < .001) (Fig. 2B ). An in vitro assay was carried out to measure invasion of cells treated with MK-2206 (BD Biosciences, San Jose, CA) toward a chemotactic agent through a thin Matrigel barrier. In Figure 2C , FaDu and SCC-1 cells were shown to migrate significantly less when treated with MK-2206 compared to controls (P ¼ .04 and P ¼ .02, respectively).
Inhibition of AKT by MK-2206 Prevents Regional Metastasis and Improves Survival
SCC-1 tumor cells were implanted in the oral tongue of immunocompromised mice and were found to have significantly lower total bioluminescence (P ¼ .029) after 14 days of treatment compared to controls (Fig. 3A) . Tumor . Cell invasion assay showed significantly less cellular chemotaxis following 24-hour treatment with MK-2206 in both FaDu (P ¼ .04) and SCC-1 (P ¼ .02) cells (C). *P < .05; **P < .01; ***P < .001. size was smaller measured by bioluminescence (Fig. 3B) (P < .001) and by digital calipers (Fig. 3C ) (P ¼ .047). Histologic sections processed for H&E of the tongue tumors shows smaller tumor with area of central necrosis in MK-2206-treated samples (Fig. 3C) . Measurement of regional lymphadenopathy in the neck was performed using fluorescently labeled cetuximab after 2 weeks of treatment as previously demonstrated. 9 The rates of cervical metastasis were lower (75% vs. 25%), and the average number of positive nodes was significantly greater in control than in treated mice (Fig. 4A) (P ¼ .011) . Furthermore, MK-2206-treated animals showed improved survival (Fig. 4B ) (P ¼ .03) compared to controls.
DISCUSSION
Treatment of advanced-stage HNSCC has progressed from surgery alone toward a multimodality approach that favors development of targeted antitumor agents with nonoverlapping toxicities to decrease patient morbidity and mortality. Toxicity associated with conventional chemoradiation has slowed advances in treatment dosing rates and thus survival. 10 Anti-EGFR targeted monoclonal antibody therapy has shown survival benefits across a range of treatment settings but is currently the only targeted therapy approved for HNSCC. We and others have shown that the AKT pathway is constitutively activated in HNSCC cells and is likely an important target for future therapies. As a molecular signaling molecule distal to EGFR, AKT is a likely candidate for therapeutic intervention.
In Although AKT inhibition has not previously been shown to inhibit metastasis in HNSCC, its multifactorial involvement in cellular signaling makes it a rational candidate to inhibit tumor invasion and metastasis. Because the in vitro IC 50 of MK-2206 was 100 nM, we chose this dose for the in vitro migration assays. That a low dose of MK-2206 (100 nM) was able to inhibit cell migration in vitro suggests a potentially large therapeutic window. In the present study, nanomolar doses of MK-2206 significantly inhibited in vitro migration in both twodimensional and three-dimensional assay of tumor cell migration. This is consistent with other cancer studies showing that inhibition of AKT phosphorylation reduces cell invasion. 11 Although the mechanism of this phenomenon is unclear, some have shown a decrease in matrix metalloproteinase expression after exposure to AKT inhibitor. Orthotopic tongue tumors had a significant reduction in both tumor size and number of cervical lymph node metastases. In vivo inhibition of the AKT pathway has been shown to inhibit tumor growth and metastasis by blocking angiogenesis. 12 When treated with MK-2206, the KaplanMeier plot of their survival yielded a significant difference in survival between control and treatment populations (P ¼ .03). A transgenic thyroid cancer model has shown that increased AKT expression is associated with metastasis. 13 The mechanism by which this is accomplished appears to be multifaceted but includes reduction in glucose uptake, decreased cell motility, reduction in proliferation and induction of apoptosis as mediated by p-BAD, p-GSK3b and p-PRAS40. In the case of GSK-3b, these affects are mediated through p-AKT phosphorylation causing its proteolytic removal. This results in decreased transcription of the transmembrane protein E-cadherin that forms adhesions between adjacent cells, thus leading to cell detachment. 14 In the current study, we present novel findings that have not previously been demonstrated including the antiproliferative effect of AKT inhibition in cervical lymph node metastasis and in human tumors in vivo. MK-2206 is currently in phase II clinical trials for patients with locally advanced or metastatic solid tumors. 15 In studies using erlotinib to treat gliomas, immunohistochemical analysis of phosphorylated AKT successfully predicted response to treatment. In these studies it was also shown that patients with elevated levels of phosphorylated AKT had higher response rates and longer time to progression than patients with low levels of phosphorylated AKT. The search for molecular predictors of sensitivity to EGFR-directed treatment should therefore be extended to markers of PI3K/AKT activation, and MK-2206 may have great potential in patients refractory to anti-EGFR therapies.
CONCLUSION
This preclinical study provides evidence that a novel small molecule AKT inhibitor, MK-2206, may have promise as a single agent to reduce tumor growth and metastasis. MK-2206 was shown to inhibit growth in multiple murine models of HNSCC, as well as reduce lymph node metastasis. Based on our results, MK-2206 should be considered for further investigation as a promising treatment modality for HNSCC. 
